Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470884 | 0.89 | AKR1B1 (0.35) | AKR1B1RAB9AHTTSMN1; SMN2HTR7 | |
| SCHEMBL2472584 | 0.89 | MEN1 (0.35) | AKR1B1RAB9AHTTSMN1; SMN2HTR7 | |
| SCHEMBL2470656 | 0.88 | MMP2 (0.37) | AKR1B1RAB9AHTTSMN1; SMN2HTR7 | |
| SCHEMBL2468857 | 0.86 | AKR1B1 (0.40) | AKR1B1RAB9AHTTSMN1; SMN2HTR7 | |
| SCHEMBL2470934 | 0.85 | EGFR (0.40) | AKR1B1RAB9AHTTSMN1; SMN2EGFR | |
| SCHEMBL2467315 | 0.85 | HSD11B1 (0.37) | AKR1B1RAB9AHTTSMN1; SMN2KMT2A | |
| SCHEMBL2467461 | 0.85 | AKR1B1 (0.37) | AKR1B1RAB9AHTTSMN1; SMN2HTR7 | |
| SCHEMBL2469498 | 0.85 | ELOVL6 (0.40) | AKR1B1HTR7 | |
| SCHEMBL2469521 | 0.84 | EGFR (0.37) | AKR1B1RAB9AHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL8259774 | 0.84 | KMT2A (0.33) | AKR1B1RAB9AHTTSMN1; SMN2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | claimed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | claimed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | claimed |
| EP-1858520-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745452-B2 | Quinazolinone T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | AKR1B1 2683/4885RAB9A 905/4885HTT 489/4885 |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | AKR1B1 2683/4885RAB9A 905/4885HTT 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.